期刊文献+

转胸腺素α1基因聚球藻抗氧化作用的研究 被引量:2

A study on antioxidation of synechococcus sp. PCC 7942 withTrans-thymosin α1-gene in Mice
暂未订购
导出
摘要 本试验室已在蓝藻聚球藻中高效表达了人源胸腺素α1(thymosinα1,Tα1)基因,为研究转Tα1基因聚球藻口服后的生物活性,本研究给小鼠灌服转Tα1基因聚球藻14d,研究其对小鼠谷胱甘肽过氧化物酶(GSH-Px)、过氧化氢酶(Cat)和超氧化物歧化酶(SOD)活力以及丙二醛(MDA)含量的影响,结果表明:转胸腺素α1基因聚球藻可显著提高小鼠心、肝与肾中GSH-Px活力(P<0.01);明显提高心脏Cat活性(P<0.01);显著降低肝脏中MDA的含量(P<0.01);但对SOD活力无明显作用。提示转胸腺素α1基因聚球藻较强的抗氧化作用。 Human thymosin α1 gene was expressed effectively in Synechococcus sp. PCC 7942 and antioxidant effect of Synechococcus sp. PCC 7942 with trans-thymosin α1-gene in mice were investigated. Synechococcus sp. PCC 7942 with trans-thymosin al-gene were administrated orally 14d,Laters the results showed that the activities of glutathione peroxidase (GSH-Px) in heart、liver and kidney were increased significantly (P<0. 01);the activity of catalase (Cat) in heart was increased markedly;the content of malondialdehyde (MDA) in liver was decreased obviously (P<0.01). But no significant change in the activity of super-oxide dismutase (SOD) was observed. It indicated that Synechococcus sp. PCC 7942 with trans-thymosin α1-gene had obvious antioxidation in vivo.
出处 《中国海洋药物》 CAS CSCD 2002年第2期4-7,共4页 Chinese Journal of Marine Drugs
基金 国家海洋863课题(项目编号:819-04-03) 福建省自然科学基金项目(项目编号:c0010002)
关键词 转胸腺素α1基因聚球藻 抗氧化作用 谷胱甘肽过氧化物酶 过氧化氢酶 超氧化物歧化酶 丙二醛 synechococcus sp. PCC 7942 with trans-thymosin α1-gene antioxidation glu-tathione peroxidase (GSH-Px) catalase (Cat) superoxide dismutase (SOD) malondialde-hyde (MDA)
  • 相关文献

参考文献5

二级参考文献8

共引文献121

同被引文献16

  • 1Carr N G, Whitton B A. The biology of Cyanobacteria[M]. Oxford:Black wall Scientific Publications, 1982.1--20.
  • 2Low TL, Thurman G B, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alphal and polypeptide betal from calf thymus[J]. J.Biol. Chem., 1979,254(3): 981--986.
  • 3Low T L , Goldstein A L. The chemistry and biology of thymosiru II. Amino acid sequence analysis of thymosin alphal and polypeptide betal [J]. J. Biol.Chem. , 1979, 254(3): 987--995.
  • 4Week P K, May L, Week C J. Gamma interferon production by different populations of human splenic lymphoeytes[J]. J. Interferon Res., 1983, 3(1): 121--128.
  • 5Ohta Y, Tezuka E, Tamura S, et al. Thymosin-alpha 1 increases the capability to produce interleukin-3 but not interleukin-2 in nu/nu mice[J]. J. Biol. Response Mod. , 1987, 6(2): 181--193.
  • 6Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin-alphal and low-dose interferon-al-pha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial[J]. Anticancer Res. , 1996,16(2): 1 001--1 004.
  • 7Mutchnick M G, Appelman H D, Chung H T, et al.Thymosin treatment of chronic hepatitis B: a placebocontrolled pilot trial [J]. Hepatology, 1991, 14 (3) :409--415.
  • 8Tang J H, Yeh C T, Chen T C, et al. Emergence of an S gene mutant during thymosin alphal therapy in a patient with chronic hepatitis B[J]. J. Infect. Dis. ,1998, 178(3): 866--869.
  • 9Moscarella S, Buzzelli G, RomaneUi R G, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results[J]. Liver, 1998,18(5): 366--369.
  • 10Pica F, Fraschetti M, Matteucci C,et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma[J]. Anticancer Res. , 1998, 18 (5A):3 571--3 578.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部